Last reviewed · How we verify
Triamcinalone Acetonide
Triamcinalone Acetonide is a Small molecule drug developed by Atsena Therapeutics Inc.. It is currently in Phase 1 development.
Triamcinalone Acetonide is a small molecule used in the treatment of various conditions, including Leber Congenital Amaurosis and Knee Osteoarthritis. It is administered through subretinal injection or possibly other routes, as indicated by studies on ATSN-101, a formulation of Triamcinalone Acetonide.
-
Baseline phase 1 → approval rate
+9.6pp
Industry-wide phase 1 drugs reach approval ~9.6% of the time (BIO/Informa 2023 industry benchmark across all therapeutic areas).
| Regulator | Country | Likely year | Lag vs FDA |
|---|---|---|---|
| FDA | US | 2033–2036 | — |
| EMA | EU | 2034–2037 | +0.7 yr |
| MHRA | GB | 2034–2037 | +0.7 yr |
| Health Canada | CA | 2034–2038 | +0.9 yr |
| TGA | AU | 2034–2038 | +1.2 yr |
| PMDA | JP | 2034–2038 | +1.5 yr |
| NMPA | CN | 2035–2039 | +2.3 yr |
| MFDS | KR | 2034–2038 | +1.4 yr |
| CDSCO | IN | 2034–2039 | +1.8 yr |
| ANVISA | BR | 2035–2039 | +2.3 yr |
Hover any row for the lag rationale. Lag estimates are reduced when the drug has FDA Breakthrough or EMA PRIME designation (sponsors file globally in parallel).
Estimate based on the BIO/Informa industry phase transition rates plus per-drug modifiers for therapeutic area, sponsor type, FDA designations, mechanism, and trial design. Per-jurisdiction lags from Tufts CSDD international approval studies. Not investment, clinical or regulatory advice. Methodology: /methodology#likelihood.
At a glance
| Generic name | Triamcinalone Acetonide |
|---|---|
| Sponsor | Atsena Therapeutics Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Efficacy of Micro-fragmented Adipose Tissue Injection for Knee Osteoarthritis. (NA)
- Study of Subretinally Injected ATSN-101 Administered in Patients With Leber Congenital Amaurosis Caused by Biallelic Mutations in GUCY2D (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triamcinalone Acetonide CI brief — competitive landscape report
- Triamcinalone Acetonide updates RSS · CI watch RSS
- Atsena Therapeutics Inc. portfolio CI
Frequently asked questions about Triamcinalone Acetonide
What is Triamcinalone Acetonide?
Who makes Triamcinalone Acetonide?
What development phase is Triamcinalone Acetonide in?
Related
- Manufacturer: Atsena Therapeutics Inc. — full pipeline
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing